As of 2026-09-10, the EV/EBITDA ratio of Cara Therapeutics Inc (CARA) is 0.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CARA's latest enterprise value is -13.59 mil USD. CARA's TTM EBITDA according to its financial statements is -61.10 mil USD. Dividing these 2 quantities gives us the above CARA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.7x - 12.8x | 8.2x |
| Forward P/E multiples | 11.4x - 15.8x | 14.4x |
| Fair Price | (144.39) - (162.57) | (142.11) |
| Upside | -2814.0% - -3155.8% | -2771.3% |
| Date | EV/EBITDA |